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Abstract
Background: Differences in access to care and treatment have been reported in Eastern Europe, a region with one of the
fastest growing HIV epidemics, compared to the rest of Europe. This analysis aimed to establish whether there are regional
differences in the mortality rate of HIV-positive individuals across Europe, and Argentina.
Methods: 13,310 individuals under follow-up were included in the analysis. Poisson regression investigated factors
associated with the risk of death.
Findings: During 82,212 person years of follow-up (PYFU) 1,147 individuals died (mortality rate 14.0 per 1,000 PYFU (95%
confidence interval [CI] 13.1–14.8). Significant differences between regions were seen in the rate of all-cause, AIDS and non-
AIDS related mortality (global p,0.0001 for all three endpoints). Compared to South Europe, after adjusting for baseline
demographics, laboratory measurements and treatment, a higher rate of AIDS related mortality was observed in East Europe
(IRR 2.90, 95%CI 1.97–4.28, p,.0001), and a higher rate of non-AIDS related mortality in North Europe (IRR 1.51, 95%CI 1.24–
1.82, p,.0001). The differences observed in North Europe decreased over calendar-time, in 2009–2011, the higher rate of
non-AIDS related mortality was no longer significantly different to South Europe (IRR 1.07, 95%CI 0.66–1.75, p = 0.77).
However, in 2009–2011, there remained a higher rate of AIDS-related mortality (IRR 2.41, 95%CI 1.11–5.25, p = 0.02) in East
Europe compared to South Europe in adjusted analysis.
Interpretations: There are significant differences in the rate of all-cause mortality among HIV-positive individuals across
different regions of Europe and Argentina. Individuals in Eastern Europe had an increased risk of mortality from AIDS related
causes and individuals in North Europe had the highest rate of non-AIDS related mortality. These findings are important for
understanding and reviewing HIV treatment strategies and policies across the European region.
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Introduction
Mortality in HIV-positive individuals continues to decrease due
to improvements in combination antiretroviral therapy (cART)
and its availability, although it remains higher than in the general
population [1]. A high proportion of the mortality observed in
HIV-positive individuals is now due to non-AIDS related causes
[2,3]. However, the incidence of non-AIDS related mortality, from
causes such as cardiovascular disease (CVD), liver disease, and
cancer, has also declined [3]. Drug specific toxicity, lifestyle factors
(smoking drug and alcohol misuse), co-infection with other viruses
(hepatitis B and C, human papillomavirus) and residual immuno-
deficiency are all thought to contribute to the higher relative risk of
non-AIDS related mortality observed in HIV-positive individuals
compared to the general population [4].
Research investigating regional differences across Europe,
particularly allowing a comparison with East Europe, is limited.
In Western and Central Europe, widespread access to antiretro-
viral therapy has led to considerable drops in AIDS related
mortality [5]. However, in Eastern Europe, a region with one of
the fastest growing HIV epidemics worldwide [6], the uptake of
cART remains low and previous studies have reported substantial
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differences in access to care and treatment compared to the rest of
Europe [7,8]. Shortly after the introduction of cART, the
EuroSIDA study reported that the all-cause mortality rate in
Western Central Europe was significantly lower than in North and
South Europe [9]. Since then, the study has grown substantially,
particularly in Eastern Europe where few cohort studies are
established. Additionally, to allow for comparisons outside of
Europe the study includes data from Argentina, where the uptake
of cART is high, with more than 95% of those in need of cART
(CD4 count ,350 cells/mm3) receiving it [10]. The study
provides a unique opportunity to establish whether, in the current
treatment era, regional differences in the mortality rate of HIV-
positive individuals remain.
Methods
Ethics Statement
Informed consent and ethics committee approval were obtained
in each participating centre according to national guidelines. Full
study details are available at www.cphiv.dk.
Inclusion Criteria
The EuroSIDA study is a prospective study of individuals with
HIV-1 in more than 100 centres across Europe, Israel and
Argentina. To be eligible for inclusion into EuroSIDA, individuals
must be aged 16 or older and have a pre-booked outpatient
appointment at the centre. Starting in May 1994, there have been
eight different periods of enrolment in EuroSIDA (cohorts I–VIII).
Currently, 16,597 individuals are enrolled in EuroSIDA. The
study has expanded into Eastern Europe with half of the
individuals originating from Eastern European countries in Cohort
VIII. Data is collected and updated at 6-monthly intervals on
standardised recruitment and follow-up forms. Full study details
are available at www.cphiv.dk. The incidence of LTFU in
EuroSIDA has previously been reported to be fairly consistent
over time at ,5% per 100 PYFU [11]. An extensive quality
assurance program has been established that includes data
checking at the coordinating office, as well as regular monitoring
visits with source verification of all new major events, plus a
random selection of individuals followed at the clinics.
Statistical Methods
Individuals were included from baseline, defined as either 1st
January 2002 or enrolment into EuroSIDA, whichever occurred
later, this was when EuroSIDA expanded its network in East
Europe. Additionally, previous EuroSIDA studies have reported
mortality rates in earlier time periods [3,12]. Follow-up was until
death, or 6 months after their last recorded visit (to allow for
delays in reporting death), whichever occurred first. The incidence
of mortality was calculated per 1,000 person years of follow-up
(PYFU) and stratified by region. Individuals were divided into 6
regions according to country of residence as follows:
N South Europe: Greece, Israel, Italy, Portugal, Spain.
N West Central Europe: Austria, Belgium, France, Germany,
Luxembourg, Switzerland.
N North Europe: Denmark, Finland, Ireland, the Netherlands,
Norway, Sweden, the United Kingdom
N East Central Europe: Bulgaria, Croatia, the Czech Republic,
Hungary, Poland, Romania, Serbia, Slovakia
N Eastern Europe: Belarus, Estonia, Latvia, Lithuania, the
Russian Federation, Ukraine
N Argentina
In order to compare the regions of Europe and Argentina,
South Europe was chosen as the reference group as this group
contained the largest number of individuals.
For individuals who died, date and cause of death are reported
by the site investigator and, since 2004, a Coding Causes of Death
in HIV (CoDe) case report form is additionally completed for each
fatal case and CoDe methods used to determine the underlying
cause of death [13]. Deaths reported without a known cause were
classified as either unknown AIDS or unknown non-AIDS
mortality according to earlier developed methods [14].
Poisson regression analyses were used to investigate factors
associated with the incidence of mortality. Variables investigated
were age, gender, ethnic origin, smoking status, anaemia,
hypertension, diabetes, hepatitis B and C status, HIV transmission
group, CD4 count, any previous AIDS defining illnesses and year
of follow-up. Age and year of follow-up were treated as continuous
variables. CD4 count was categorised (,200, 200–349, 350–500,
$500 cell/mm3, missing) to allow for patients with missing values
to remain in the analysis. Further treatment for HIV was split into
4 categories, not on cART, on cART with a viral load
,500 copies/ml, on cART with a viral load $500 copies/ml,
or on cART with no viral load measurement available. cART was
defined as receiving $3 antiretrovirals. A cut-off of 500 copies/ml
was chosen as this was lower limit of detection of the viral load
assay for some individuals. Both current (time-updated) and
baseline values were investigated for variables that could change
over time. Factors that were significant in univariate analysis
(p,0.1) were included in multivariate analyses.
Individuals were classed as Hepatitis B positive if they had a
positive HBV surface antigen test recorded and Hepatitis C
positive if they had a positive HCV antibody test. Hypertension
was defined as a diastolic blood pressure $90 or a systolic blood
pressure $140 (mmHg) or receiving anti-hypertensive medication.
If a diagnosis of insulin dependent diabetes was reported by the
investigating centre or if an individual was receiving anti-diabetic
medication they were classed as diabetic. Anaemia was defined as
a haemoglobin level #12 or #14 (mg/dl) for females and males
respectively [15]. Smoking status was defined as either never,
current, previous or unknown.
All analysis was performed using SAS 9.1 (SAS institute, Cary
North Carolina, USA).
Results
13,310 HIV-positive individuals were included in the analysis.
There were clear differences in demographics across the regions
(table 1). In East Europe, individuals were more likely to be
younger (median age 30), female (42%) and infected via
intravenous drug use [IDU] (49%) or heterosexual sex (41%). In
contrast the majority of the individuals in West Central (45%), and
North Europe (59%) were infected through homosexual sex.
Similar baseline CD4 counts were observed across the regions. In
South, West Central, North, East Central Europe and Argentina
around 75–80% were on cART at baseline compared to only 30%
in East Europe. In these individuals on cART, 62% in East
Europe had a viral load ,500 copies/ml compared to 70–85% in
the other regions.
From 2002 until a median last follow-up date of September
2011 (interquartile range [IQR] April 09-December 2011),
individuals were followed for a total of 82,212 PYFU. During
this time 1,147 patients died, the crude mortality rate was 14.0 per
1,000 PYFU (95% confidence interval [CI] 13.1–14.8). The
majority (837, 73%) were attributed to non-AIDS related causes,
the crude mortality rate was 10.2 non-AIDS related deaths per
AIDS and Non-AIDS Mortality Rates in Europe
PLoS ONE | www.plosone.org 2 July 2012 | Volume 7 | Issue 7 | e41673
1,000 PYFU (95% CI 9.5–10.9) compared to 3.8 AIDS related
deaths per 1,000 PYFU (95% CI 3.4–4.2). Figure 1 shows the
crude mortality rate for all cause, AIDS and non-AIDS related
causes by region. Significant differences in mortality were seen
across the 6 different regions (global p,0.0001 for all three
endpoints). Higher all-cause mortality rates were observed in
North and East Europe compared to the other regions. In East
Europe a higher rate of AIDS related mortality was observed, the
crude mortality rate due to AIDS related causes in East Europe
was over three times higher than in South Europe (incidence rate
ratio [IRR] 3.41, 95%CI 2.48–4.68, p,0001). In contrast, a
higher rate of non-AIDS related mortality was observed in North
Europe, compared to South Europe, the crude rate of non-AIDS
related mortality in North Europe was 1.4 times higher (IRR 1.41,
95% CI 1.18–1.69, p,0001).
Table 2 shows the characteristics of the individuals who died at
the time of their death in each of the 6 regions. Those in East
Europe were younger at the time of their death and had lower
CD4 counts. A higher proportion on individuals in East Europe
(66%) and Argentina (68%) had experienced an AIDS event prior
to their death than in the other regions. In contrast, in those dying
in South, West Central, North, East Central Europe and
Argentina around 30–40% had been diagnosed with a non-AIDS
Table 1. Baseline characteristics (baseline was defined as either 1st January 2002 or enrolment into EuroSIDA which ever occurred
later).
South Europe
West central
Europe North Europe
East Central
Europe East Europe Argentina
Total (N,% of total) 3246 24.4% 2920 21.9% 2866 21.5% 1700 12.8% 2082 15.6% 496 3.7%
Gender (N.%) Male 2391 73.7% 2246 76.9% 2332 81.4% 1221 71.8% 1171 57.7% 308 62.1%
Race (N.%) White 2971 91.5% 2102 72.0% 2426 84.6% 1674 98.5% 2074 102.3% 489 98.6%
Exposure Group Homosexual 1101 33.9% 1307 44.8% 1693 59.1% 627 36.9% 154 7.6% 126 25.4%
(N.%) Injection Drug
User
949 29.2% 406 13.9% 317 11.1% 449 26.4% 996 49.1% 62 12.5%
Heterosexual 988 30.4% 849 29.1% 684 23.9% 490 28.8% 830 40.9% 292 58.9%
Prior AIDS (N.%) 853 26.3% 951 32.6% 915 31.9% 424 24.9% 402 19.8% 161 32.5%
Hepatitis B (N.%) Negative 2186 67.3% 2308 79.0% 2339 81.6% 1408 82.8% 1653 81.5% 357 72.0%
Positive 162 5.0% 202 6.9% 206 7.2% 81 4.8% 112 5.5% 26 5.2%
Unknown 898 27.7% 410 14.0% 321 11.2% 211 12.4% 317 15.6% 113 22.8%
Hepatitis C (N.%) Negative 1595 49.1% 1982 67.9% 1839 64.2% 995 58.5% 699 34.5% 295 59.5%
Positive 755 23.3% 460 15.8% 329 11.5% 480 28.2% 1014 50.0% 91 18.3%
Unknown 896 27.6% 478 16.4% 698 24.4% 225 13.2% 369 18.2% 110 22.2%
Hypertension No 1629 50.2% 1136 38.9% 862 30.1% 1045 61.5% 1295 63.9% 292 58.9%
Yes 488 15.0% 538 18.4% 505 17.6% 327 19.2% 119 5.9% 42 8.5%
Unknown 1129 34.8% 1246 42.7% 1499 52.3% 328 19.3% 668 32.%9 162 32.7%
Diabetes No 2904 89.5% 2012 68.9% 2614 91.2% 1609 94.6% 2061 101.6% 489 98.6%
Yes 180 5.5% 148 5.1% 93 3.2% 44 2.6% 5 0.2% 5 1.0%
Unknown 162 5.0% 760 26.0% 159 5.5% 47 2.8% 16 0.8% 2 0.4%
Anaemia No 2194 67.6% 1904 65.2% 1642 57.3% 776 45.6% 197 9.7% 187 37.7%
Yes 782 24.1% 747 25.6% 911 31.8% 295 17.4% 110 5.4% 205 41.3%
Unknown 270 8.3% 269 9.2% 313 10.9% 629 37.0% 1775 87.5% 104 21.0%
Smoking Never 706 21.7% 765 26.2% 576 20.1% 416 24.5% 387 19.1% 146 29.4%
Current 1495 46.1% 1179 40.4% 1156 40.3% 872 51.3% 1142 56.3% 169 34.1%
Previous 623 19.2% 669 22.9% 643 22.4% 306 18.0% 369 18.2% 146 29.4%
Unknown 422 13.0% 307 10.5% 491 17.1% 106 6.2% 184 9.1% 35 7.1%
On cART (N.%) 2558 78.8% 2170 74.3% 2286 79.8% 1269 74.6% 603 29.7% 367 74.0%
On cART with viral load,500copies/ml
(N, % on cART)
1795 70.2% 1732 79.3% 1927 84.3% 978 77.0% 371 61.5% 253 68.9%
Missing viral load on cART (N, % on cART) 16 0.6% 5 0.2% 11 0.5% 20 1.6% 40 6.6% 9 2.5%
Age (median, IQR) 40 35–46 42 37–49 43 37–50 35 30–42 30 25–36 37 31–43
CD4 count (median, IQR) 450 291–650 432 286–621 420 279–598 373 242–
543
407 259–575 342 201–510
Missing CD4 count (N, %) 20 0.6% 10 0.3% 15 0.5% 6 0.4% 96 4.6% 4 0.8%
Baseline date (median, IQR) 1/02 1/02–
12/03
1/02 1/02–12/
05
1/02 1/02–12/03 1/04 1/02–
12/08
2/06 4/04–6/
08
2/06 11/03–6/
06
doi:10.1371/journal.pone.0041673.t001
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event prior to their death, whereas only 17% had been diagnosed
in East Europe.
Table 3 gives the results of the Poisson regression analysis and
presents the incidence rate ratios for all-cause, AIDS and non-
AIDS related mortality for the five regions compared to South
Europe. Adjusting for gender, age, HIV exposure group, AIDS
diagnosis prior to baseline, non-AIDS event prior to baseline,
hepatitis B and C status, hypertension, anaemia, baseline CD4
count, baseline date and baseline on cART/viral load status
accounted for some of the higher rate of AIDS-related mortality
observed in East Europe, though the rate of AIDS-related
mortality was still more than double the rate in South Europe
(IRR 2.27, 95%CI 1.42–3.46, p = 0.0006). Further, modelling age,
hepatitis B and C status, hypertension, anaemia, CD4 count, year
of follow-up and on cART viral load as time updated covariates
the rate of AIDS related mortality was more than three times
higher in East Europe compared to South.
A higher incidence of non-AIDS related mortality was observed,
after adjusting for baseline variables (listed in the footnote of
table 3), in North Europe (IRR 1.63, 95%CI 1.34–1.99, p,0001),
East Central Europe (IRR 1.31, 95%CI 1.01–1.70, p = 0.04) and
East Europe (IRR 1.81, 95%CI 1.27–2.57, p = 0.001) compared to
South Europe (Table 3). After including time-updated covariates
in the model the increased rate was no longer significant in East
Central Europe (IRR 1.22, 95% CI 0.95–1.58, p = 0.11) or East
Europe (IRR 1.29, 95% CI 0.98–1.71, p = 0.07) but there
remained a significantly increased rate of mortality in North
Europe (IRR 1.51, 95% CI 1.24–1.82, p,0001).
In the adjusted analyses, increasing year of follow-up was
associated with a significantly lower rate of both AIDS (IRR 0.91,
95%CI 0.87–0.95, p,.0001 and non-AIDS related mortality (IRR
0.90, 95%CI 0.88–0.92, p,0001). The test for interaction
between region and calendar year of follow-up was significant
for all-cause (p = 0.02) and AIDS related (p = 0.05) mortality,
indicating that the effect of calendar year of follow-up on mortality
rate may be different in each region, although it was non-
significant for non-AIDS related mortality (p = 0.10). Figure 2
shows the adjusted incidence rate ratio for mortality per calendar
year of follow-up stratified by region, from the fully adjusted
model. Significant decreases over time in all-cause mortality rates
were observed in West Central (IRR 0.90 per calendar year later,
95%CI 0.85–0.95, p = 0.0002), North (IRR 0.85 per calendar year
later, 95%CI 0.82–0.89, p,0001), and East Europe (IRR 0.89 per
calendar year later, 95%CI 0.84–0.95, p0.0005). No significant
changes over time in all-cause mortality were observed in South
(p = 0.32) or East Central Europe (p = 0.37). Argentina was
excluded from this analysis due to the limited number of patients.
Despite the observed decrease in mortality in East Europe over
time, in the most recent period, 2009–2011, there remained a
higher rate of all-cause (IRR 1.50, 95%CI 1.50–2.38, p = 0.08)
and AIDS-related mortality (IRR 2.41, 95%CI 1.11–5.25,
p = 0.02) compared to South Europe in adjusted analysis.
However, in 2009–2011, the significantly higher rate in North
Europe was no longer observed for all-cause (IRR 0.91, 95%CI
0.58–1.42, p = 0.18) or non-AIDS related mortality (IRR 1.07,
95%CI 0.66–1.75, p = 0.77), suggesting that the differences in
North Europe, relative to South, are decreasing over time.
Figure 1. Crude mortality rate across the six different regions. Cause of death are reported by the site investigator and, since 2004, a Coding
of Death in HIV (CoDe) case report form is additionally completed for each fatal case and CoDe methods used to determine the underlying cause of
death.
doi:10.1371/journal.pone.0041673.g001
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Discussion
EuroSIDA is unique amongst studies of HIV-positive individ-
uals in terms of its coverage across the entire continent of Europe.
The results of this study with over 67,000 PYFU found significant
differences in mortality rates across regions of Europe and
Argentina. In particular, individuals in East Europe were found
to have a higher mortality rate from AIDS related causes and
individuals in North Europe a higher rate of non-AIDS related
mortality. Similar rates of both AIDS and non-AIDS related
mortality were seen across the other regions of Europe and
Argentina. The mortality rate decreased over time particularly in
West Central, North and East Europe.
Differences in the incidence of AIDS related mortality could
partly be explained by variations in patient demographics
including CD4 count and use of effective cART regimens. The
epidemic in Eastern Europe is more recent, from 1995 there has
been a rapid increase in HIV infections [16]. Since then a number
of countries in the region have expanded access to antiretroviral
coverage although treatment coverage remains low. UNAIDS
estimated that in 2009 19% of those eligible for treatment in East
Europe were accessing it, an estimated increase of 34% since the
previous year [16]. In our study, after adjustment, the rate of
AIDS related mortality appeared to be decreasing over time in
East Europe, which may reflect improvements in antiretroviral
coverage. However, after adjustment for time-updated CD4 count,
use of cART, viral load and other factors, regional differences in
AIDS related mortality were still significant, indicating that the
differences cannot be fully explained by those variables collected
and included in our models.
A high proportion of patients in East Europe are infected via
IDU [17]. This was accounted for in the adjusted analysis but,
IDU populations may differ across the regions. Several factors
have been identified as contributing to the excess risk of mortality
observed in IDUs in the cART era including decreased access and
adherence to cART [18,19], and more comorbidities such as co-
infection with hepatitis C [20,21]. In West Central Europe
coverage of HIV services in IDU populations has been reported to
be high, particularly access to cART [22]. However in East
Europe services are low, there are low levels of needle exchange
programmes [23] and very few IDUs have been found to be
receiving antiretroviral treatment [22]. Opiate substitution pro-
grams are available in most countries but may be very limited in
East Europe. Detailed information on opiate substitution pro-
grammes or whether individuals were actively injecting drug users
was not available in this analysis. However, a sensitivity analysis,
excluding those where the reported transmission route was IDU,
found a similar increased incidence rate for East compared to
South Europe, indicating that the higher prevalence of IDU does
not account for the excess risk.
State-of-the-art care of HIV patients requires the utilisation of
multiple health care interventions, such as the procurement of
antiretroviral drugs, laboratory equipment, proper monitoring of
antiretroviral treatment effectiveness and safety, and health care
Table 2. Characteristics at time of death of 1147 patients who died between 2002–2011 across Europe and Argentina.
Region
South West Central North East Central East Argentina P-value*
N died (% of total in each region) 273 (8.4%) 208 (7.1%) 337 (11.8%) 126 (7.4%) 178 (8.6%) 25 (5.0%) ,.0001
Age (median, IQR) 47 (42–57) 48 (43–59) 50 (43–59) 42 (36–54) 35 (30–41) 41 (34–48) ,.0001
CD4 count, cells/mm3 (median, IQR) 208 (78–392) 249 (85–450) 260 (113–452) 236 (90–416) 156 (45–296) 58 (24–136) 0.0002
Missing CD4 count (N, %) 56 (20.5%) 39 (18.8%) 78 (23.2%) 23 (18.3%) 82 (46.1%) 11 (44.0%)
Ever started cART (N, %) 261 (95.6%) 195 (93.8%) 325 (96.4%) 112 (89.9%) 89 (50.0%) 24 (96.0%) ,.0001
HIV viral load ,500 copies/ml (N,% with viral
load measured)
128 (63.1%) 101 (61.6%) 187 (71.4%) 48 (58.5%) 17 (37.0%) 6 (60.0%) 0.0005
Missing viral load (N,%) 70 (25.6%) 44(21.2%) 75 (22.3%) 44 (34.9%) 132 (74.2%) 15 (60.0%)
AIDS reported prior to death (N, %) 159 (58.2%) 123 (59.1%) 168 (49.9%) 75 (59.5%) 118 (66.3%) 17 (68.0%) ,.0001
Most recent AIDS diagnosis (N, % of AIDS
diagnosis)
Oesophageal candidiasis 12 (7.6%) 23 (18.7%) 32 (19.1%) 7 (9.3%) 26 (22.0%) 2 (11.8%)
PCP 14 (8.8%) 9 (7.3%) 25 (14.9%) 7 (9.3%) 8 (6.8%) 2 (11.8%)
HIV wasting syndrome 8 (5.0%) 12 (9.8%) 10 (6.0%) 6 (8.0%) 18 (15.3%) 1 (5.9%)
Pulmonary TB 18 (11.3%) 5 (4.1%) 6 (3.6%) 7 (9.3%) 21 (17.8% 1 (5.9%)
NHL 24 (15.1%) 10 (8.1%) 20 (11.9%) 8 (10.7%) 2 (1.7%) 1 (5.9%)
Non-AIDS event prior to death (N,%) 109 (39.9%) 63 (30.3%) 107 (31.8%) 45 (35.7%) 31 (17.4%) 8 (32.0%) ,.0001
Non-AIDS events reported (N,%)
NADM 49 (17.9%) 24 (11.5%) 45 (13.3%) 18 (14.3%) 4 (2.2%) 4 (16%)
Cardiovascular disease 32 (11.7%) 30 (14.4%) 52 (15.4%) 19 (15.1%) 3 (1.7%) 1 (4%)
Pancreatitis 10 (3.7%) 7 (3.4%) 7 (2.1%) 4 93.2%) 10 (5.6%) 0 (0%)
Liver related event 25 (9.2%) 9 (4.3%) 11 (3.3%) 10 (7.9%) 17 (9.6%) 4 (16%)
End-stage renal disease 10 (3.7%) 7 (3.4%) 5 (1.5%) 0 (0%) 1 (0.6%) 0(0%)
*Chi-squared test for categorical variables and Kruskal-Wallis for continuous variables. IQR; Inter-quartile range, PCP: Pneumocystis jiroveci pneumonia,
TB: mycobacterium tuberculosis, NHL: non-Hodgkin’s lymphoma, NADM: non-AIDS defining malignancy.
doi:10.1371/journal.pone.0041673.t002
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infrastructure in general [16]. Not all differences in patient care will
have been captured by the use of effective cART, and overall lower
levels of patient care in East Europe, may play a significant role in the
higher rate of AIDS related mortality. Socio-economic and
infrastructure aspects, for which we do not have data [24], may also
play a role.
An increased rate of non-AIDS mortality was found in patients
in North Europe compared to South Europe, and these differences
could not be explained by adjusting for differences in patient
demographics, treatment or other risk factors that were measured
such as smoking status, co-infection and CVD risk factors, either at
baseline or time-updated. However, the rate of non-AIDS related
mortality does appears to be decreasing over time in North Europe
with no difference observed in the most recent time period. The
differences in non-AIDS mortality are probably not driven by poor
patient care but by underlying differences in population morbidity
and mortality. Smoking and excessive alcohol are found at an
increased level in the HIV-positive population compared to the
general population [25,26] and could not be fully adjusted for in
these analyses. Further, Mediterranean diet has been found to be
associated with a lower risk of all-cause mortality, in particular due
to CVD and cancer [27]. A recent study found that middle-aged
men in North Europe had a 5% and woman 28% higher risk of
all-cause mortality compared to South [28]. Although we have
accounted for CVD factors such as diabetes and hypertension,
these data were not available for all patients. Additionally, data on
alcohol use was not available for this analysis although it has
recently been added to the EuroSIDA follow-up forms. Further-
more, if HIV infection is accelerating the aging process [29],
certain factors in North Europe such as a high intake of animal fat,
smoking, and alcohol use, may be acting with this and could partly
explain the differences observed, although we found no evidence
Table 3. Results from univariate and multivariate Poisson regression analysis investigating mortality rates by region (South is the
reference region).
All-cause mortality Univariate Multivariatea Multivariateb
Region IRR 95% CI
p-
value IRR 95% CI
p-
value IRR 95% CI p-value
South Europe 1.00 – – 1.00 – – 1.00 – –
West Central Europe 0.83 0.69–0.99 0.04 0.99 0.82–1.20 0.90 0.85 0.70–1.03 0.09
North Europe 1.30 1.11–1.53 0.001 1.50 1.26–1.78 ,.0001 1.37 1.15–1.62 0.0003
East Central Europe 0.96 0.77–1.18 0.67 1.31 1.05–1.64 0.01 1.28 1.03–1.59 0.02
East Europe 1.65 1.36–1.99 ,.0001 2.07 1.57–2.73 ,.0001 1.77 1.42–2.20 ,.0001
Argentina 0.68 0.45–1.03 0.06 0.99 0.65–1.52 0.97 0.77 0.50–1.16 0.21
AIDS related mortality Univariate Multivariatec Multivariated
Region IRR 95% CI p-
value
IRR 95% CI p-value IRR 95% CI p-value
South Europe 1.00 – – 1.00 – – 1.00 – –
West Central Europe 0.77 0.53–1.13 0.18 0.84 0.57–1.23 0.36 0.72 0.49–1.06 0.09
North Europe 0.94 0.66–1.34 0.73 1.09 0.75–1.58 0.66 1.01 0.70–1.46 0.95
East Central Europe 1.16 0.78–1.74 0.46 1.29 0.84–1.97 0.24 1.43 0.93–2.19 0.10
East Europe 3.41 2.48–4.68 ,.0001 2.27 1.42–3.64 0.0006 2.90 1.97–4.28 ,.0001
Argentina 1.36 0.73–2.51 0.33 1.03 0.54–1.95 0.93 1.01 0.53–1.90 0.98
Non-AIDS related mortality Univariate Multivariatea Multivariateb
Region IRR 95% CI p-value IRR 95% CI p-value IRR 95% CI p-value
South Europe 1.00 – – 1.00 – – 1.00 – –
West Central Europe 0.85 0.69–1.04 0.11 1.01 0.81–1.26 0.92 0.88 0.70–1.10 0.27
North Europe 1.41 1.18–1.69 0.0002 1.63 1.34–1.99 ,.0001 1.51 1.24–1.82 ,.0001
East Central Europe 0.89 0.69–1.14 0.35 1.31 1.01–1.70 0.04 1.22 0.95–1.58 0.11
East Europe 1.09 0.85–1.39 0.51 1.81 1.27–2.57 0.001 1.29 0.98–1.71 0.07
Argentina 0.47 0.27–0.82 0.008 0.87 0.49–1.54 0.62 0.61 0.35–1.09 0.09
aadjusted for baseline variables gender, age, HIV exposure group, hepatitis B and C status, prior AIDS diagnosis, prior non-AIDS diagnosis, hypertension, diabetes,
anaemia, smoking status, CD4 count, baseline date and on cART viral load.
badjusted as in a but age, hepatitis B and C status, hypertension, diabetes, anaemia, smoking status, CD4 count, year of follow-up and on cART viral load were included
as time-updated covariates.
cadjusted for baseline variables gender, age, HIV exposure group, hepatitis B and C status, prior AIDS diagnosis, prior non-AIDS diagnosis, hypertension, diabetes,
anaemia, CD4 count, baseline date and on cART viral load.
dadjusted as in a but age, hepatitis B and C status, hypertension, diabetes, anaemia, CD4 count, year of follow-up and on cART viral load were included as time-updated
covariates.
doi:10.1371/journal.pone.0041673.t003
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that the relationship between age and mortality differed between
regions (data not shown).
Another possibility is that the higher observed rate in North
Europe is due to under ascertainment or incomplete reporting of
mortality in other regions. Centres in some countries may be
linked to national death registers allowing more complete
reporting of mortality or have better methods of finding patients
lost to follow-up (LTFU). LTFU in EuroSIDA is low, with
individuals in North and West Central Europe having the lowest
and those in East Europe the highest rates of LTFU in the study
[11]. To investigate biases caused by under ascertainment of death
we varied the right censoring interval from 6 months after last
follow-up visit to 3 months and 1 year. The results remained
consistent with the main analysis, suggesting that these differences
aren’t solely due to underreporting in other regions. An analysis
comparing the general HIV-negative population in these regions
may also help clarify the reasons for these differences.
Demographically, individuals enrolled in the EuroSIDA study
are fairly representative of each region based on comparisons with
data from UNAIDS [30]. However, centres included in EuroSIDA
are often university-associated clinics in larger cities, thus
individuals in these clinics may have better access to care and
may not be representative of all clinics in Europe, with potentially
better clinical outcomes. This raises most concern in Eastern
Europe, where the least favourable outcomes were seen, suggesting
that improvements in this region are urgently needed. Further,
within each of the regions some countries maybe quite heteroge-
neous in terms of their political and economic situation, however,
the groupings provide a valuable regional overview of the
differences in mortality rate across Europe.
In conclusion, differences were observed in the rate of all-cause
mortality among HIV-positive individuals across different regions
of Europe. Individuals in Eastern Europe had an increased risk of
mortality from AIDS related causes in part due to differences in
use of effective cART. Individuals in North Europe had the
highest rate of non-AIDS related mortality which could not easily
be explained but did appear to decrease over time. These findings
are important for understanding and reviewing HIV treatment
strategies and policies across the European region.
Acknowledgments
The multi-centre study group on EuroSIDA (national coordina-
tors in parenthesis).
Argentina: (M Losso), C Elias, Hospital JM Ramos Mejia, Buenos
Aires. Austria: (N Vetter), Pulmologisches Zentrum der Stadt Wien,
Vienna; R Zangerle, Medical University Innsbruck, Innsbruck. Belarus:
(I Karpov), A Vassilenko, Belarus State Medical University, Minsk, VM
Mitsura, Gomel State Medical University, Gomel; O Suetnov, Regional
AIDS Centre, Svetlogorsk. Belgium: (N Clumeck), S De Wit, M Delforge,
Saint-Pierre Hospital, Brussels; R Colebunders, Institute of Tropical
Medicine, Antwerp; L Vandekerckhove, University Ziekenhuis Gent,
Gent. Bosnia-Herzegovina: (V Hadziosmanovic), Klinicki Centar
Univerziteta Sarajevo, Sarajevo. Bulgaria: (K Kostov), Infectious
Diseases Hospital, Sofia. Croatia: (J Begovac), University Hospital of
Infectious Diseases, Zagreb. Czech Republic: (L Machala), D Jilich,
Faculty Hospital Bulovka, Prague; D Sedlacek, Charles University
Hospital, Plzen. Denmark: (J Nielsen), G Kronborg,T Benfield, M
Larsen, Hvidovre Hospital, Copenhagen; J Gerstoft, T Katzenstein, A–B E
Hansen, P Skinhøj, Rigshospitalet, Copenhagen; C Pedersen, Odense
University Hospital, Odense; L Ostergaard, Skejby Hospital, Aarhus.
Estonia: (K Zilmer), West-Tallinn Central Hospital, Tallinn; Jelena
Smidt, Nakkusosakond Siseklinik, Kohtla-Ja¨rve. Finland: (M Ristola),
Figure 2. Incidence rate ratio (IRR) for all cause, AIDS and non-AIDS related mortality per calendar year of follow-up stratified by
region. (Argentina was excluded from this analysis due to limited power). aadjusted for gender, age*, HIV exposure group, hepatitis B* and C* status,
prior AIDS diagnosis, prior non-AIDS diagnosis, hypertension*, diabetes*, anaemia*, smoking status*, CD4 count*, baseline date* and on cART viral
load*. badjusted for gender, age*, HIV exposure group, hepatitis B* and C* status, prior AIDS diagnosis, prior non-AIDS diagnosis, hypertension*,
diabetes*, anaemia*, CD4 count*, baseline date* and on cART viral load*. *time-updated.
doi:10.1371/journal.pone.0041673.g002
AIDS and Non-AIDS Mortality Rates in Europe
PLoS ONE | www.plosone.org 7 July 2012 | Volume 7 | Issue 7 | e41673
Helsinki University Central Hospital, Helsinki. France: (C Katlama),
Hoˆpital de la Pitie´-Salpe´tie`re, Paris; J-P Viard, Hoˆpital Necker-Enfants
Malades, Paris; P-M Girard, Hospital Saint-Antoine, Paris; JM Livrozet,
Hoˆpital Edouard Herriot, Lyon; P Vanhems, University Claude Bernard,
Lyon; C Pradier, Hoˆpital de l’Archet, Nice; F Dabis, D Neau, Unite´
INSERM, Bordeaux. Germany: (J Rockstroh), Universita¨ts Klinik Bonn;
R Schmidt, Medizinische Hochschule Hannover; J van Lunzen, O Degen,
University Medical Center Hamburg-Eppendorf, Infectious Diseases Unit,
Hamburg; HJ Stellbrink, IPM Study Center, Hamburg; S Staszewski, JW
Goethe University Hospital, Frankfurt; J Bogner, Medizinische Poliklinik,
Munich; G. Fa¨tkenheuer, Universita¨t Ko¨ln, Cologne. Greece: (J
Kosmidis), P Gargalianos, G Xylomenos, J Perdios, Athens General
Hospital; G Panos, A Filandras, E Karabatsaki, 1st IKA Hospital; H
Sambatakou, Ippokration Genereal Hospital, Athens. Hungary: (D
Banhegyi), Szent La´slo´ Hospital, Budapest. Ireland: (F Mulcahy), St.
James’s Hospital, Dublin. Israel: (I Yust), D Turner, M Burke, Ichilov
Hospital, Tel Aviv; S Pollack, G Hassoun, Rambam Medical Center,
Haifa; S Maayan, Hadassah University Hospital, Jerusalem. Italy: (S
Vella), Istituto Superiore di Sanita`, Rome; R Esposito, I Mazeu, C Mussini,
Universita` Modena, Modena; C Arici, Ospedale Riuniti, Bergamo; R
Pristera, Ospedale Generale Regionale, Bolzano; F Mazzotta, A Gabbuti,
Ospedale S Maria Annunziata, Firenze; V Vullo, M Lichtner, University di
Roma la Sapienza, Rome; A Chirianni, E Montesarchio, M Gargiulo,
Presidio Ospedaliero AD Cotugno, Monaldi Hospital, Napoli; G
Antonucci, A Testa, P Narciso, C Vlassi, M Zaccarelli, Istituto Nazionale
Malattie Infettive Lazzaro Spallanzani, Rome; A Lazzarin, A Castagna, N
Gianotti, Ospedale San Raffaele, Milan; M Galli, A Ridolfo, Osp. L.
Sacco, Milan; A d’Arminio Monforte, Istituto Di Clinica Malattie Infettive
e Tropicale, Milan. Latvia: (B Rozentale), I Zeltina, Infectology Centre of
Latvia, Riga. Lithuania: (S Chaplinskas), Lithuanian AIDS Centre,
Vilnius. Luxembourg: (R Hemmer), T Staub, Centre Hospitalier,
Luxembourg. Netherlands: (P Reiss), Academisch Medisch Centrum
bij de Universiteit van Amsterdam, Amsterdam. Norway: (V Ormaasen),
A Maeland, J Bruun, Ulleva˚l Hospital, Oslo. Poland: (B Knysz) J
Gasiorowski, Medical University, Wroclaw; A Horban, E Bakowska,
Centrum Diagnostyki i Terapii AIDS, Warsaw; A Grzeszczuk, R Flisiak,
Medical University, Bialystok; A Boron-Kaczmarska, M Pynka, M
Parczewski, Medical Univesity, Szczecin; M Beniowski, E Mularska,
Osrodek Diagnostyki i Terapii AIDS, Chorzow; H Trocha, Medical
University, Gdansk; E Jablonowska, E Malolepsza, K Wojcik, Wojewodzki
Szpital Specjalistyczny, Lodz. Portugal: (F Antunes), M Doroana, L
Caldeira, Hospital Santa Maria, Lisbon; K Mansinho, Hospital de Egas
Moniz, Lisbon; F Maltez, Hospital Curry Cabral, Lisbon. Romania: (D
Duiculescu), Spitalul de Boli Infectioase si Tropicale: Dr. Victor Babes,
Bucarest. Russia: (A Rakhmanova), Medical Academy Botkin Hospital,
St Petersburg; N Zakharova, St Petersburg AIDS Centre, St Peterburg; S
Buzunova, Novgorod Centre for AIDS, Novgorod. Serbia: (D Jevtovic),
The Institute for Infectious and Tropical Diseases, Belgrade. Slovakia: (M
Mokra´sˇ), D Stanekova´, De´rer Hospital, Bratislava. Slovenia: (J Tomazic),
University Clinical Centre Ljubljana, Ljubljana. Spain: (J Gonza´lez-
Lahoz), V Soriano, P Labarga, J Medrano, Hospital Carlos III, Madrid; S
Moreno, J. M. Rodriguez, Hospital Ramon y Cajal, Madrid; B Clotet, A
Jou, R Paredes, C Tural, J Puig, I Bravo, Hospital Germans Trias i Pujol,
Badalona; JM Gatell, JM Miro´, Hospital Clinic i Provincial, Barcelona; P
Domingo, M Gutierrez, G Mateo, MA Sambeat, Hospital Sant Pau,
Barcelona. Sweden: (A Karlsson), Venhaelsan-Sodersjukhuset, Stock-
holm; L Flamholc, Malmo¨ University Hospital, Malmo¨. Switzerland: (B
Ledergerber), R Weber, University Hospital, Zu¨rich; P Francioli, M
Cavassini, Centre Hospitalier Universitaire Vaudois, Lausanne; B
Hirschel, E Boffi, Hospital Cantonal Universitaire de Geneve, Geneve;
H Furrer, Inselspital Bern, Bern; M Battegay, L Elzi, University Hospital
Basel. Ukraine: (E Kravchenko), N Chentsova, Kiev Centre for AIDS,
Kiev; V Frolov, G Kutsyna, Luhansk State Medical University; Luhansk; S
Servitskiy, Odessa Region AIDS Center, Odessa; M Krasnov, Kharkov
State Medical University, Kharkov. United Kingdom: (S Barton), St.
Stephen’s Clinic, Chelsea and Westminster Hospital, London; AM
Johnson, D Mercey, Royal Free and University College London Medical
School, London (University College Campus); A Phillips, MA Johnson, A
Mocroft, Royal Free and University College Medical School, London
(Royal Free Campus); M Murphy, Medical College of Saint Bartholomew’s
Hospital, London; J Weber, G Scullard, Imperial College School of
Medicine at St. Mary’s, London; M Fisher, Royal Sussex County Hospital,
Brighton; C Leen, Western General Hospital, Edinburgh.
Steering Committee: J Gatell, B Gazzard, A Horban, J Lundgren, I
Karpov, B Ledergerber, M Losso, A D’Arminio Monforte, C Pedersen, A
Phillips, A Rakhmanova, M Ristola, P Reiss, J Rockstroh (Chair), S De Wit
(Vice-Chair)
Coordinating Centre Staff: O Kirk, A Mocroft, A Cozzi-Lepri, D
Grint, M Ellefson, D Podlekareva, J Kjær, L Peters, J Reekie, J Kowalska, J
Nielsen, J Tverland, A H Fischer
EuroSIDA representatives to EuroCoord: O. Kirk, A. Mocroft, J.
Grarup, S. deWitt, P. Reiss, A. Cozzi-Lepri, R. Thiebaut, J. Rockstroh, D.
Burger, R. Paredes, J. Kjær
Author Contributions
Conceived and designed the experiments: JDL OK AM. Analyzed the
data: JMR JDK. Wrote the paper: JMR. National data coordination: IK
JR AK AR AH. Interpretation of results: JMR JDK JDL OK AM.
Critically revised manuscript: JDK IK JR AK AR AH JDL OK AM.
Approved the final version of the manuscript: JMR JDK IK JR AK AR
AH JDL OK AM STUDY PI: JDL OK AM.
References
1. Antiretroviral Therapy Cohort Collaboration (2008) Life expectancy of
individuals on combination antiretroviral therapy in high-income countries: a
collaborative analysis of 14 cohort studies. Lancet 372: 293–299.
2. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, et al. (2008) Changes in
causes of death among adults infected by HIV between 2000 and 2005: The
‘‘Mortalite 2000 and 2005’’ surveys (ANRS EN19 and Mortavic). J Acquir
Immune Defic Syndr 48: 590–598.
3. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, et al. (2002) Changes in
the cause of death among HIV positive subjects across Europe: results from the
EuroSIDA study. AIDS 16: 1663–1671.
4. Deeks SG, Phillips AN (2009) HIV infection, antiretroviral treatment, ageing,
and non-AIDS related morbidity. BMJ 338: a3172.
5. Joint United Nations Programme on HIV/AIDS (UNAIDS) (2009) Fact Sheet,
North America and Western and Central Europe. Latest epidemiological trends.
6. UNAIDS, World Health Organization (2009) 09 AIDS epidemic update. 1–100.
7. Podlekareva D, Reekie J, Rakhmanova A, Horban A, Mocroft A, et al. (2008)
Indicators of the use of healthcare interventions across Europe.
8. Podlekareva D, Bannister W, Mocroft A, Abrosimova L, Karpov I, et al. (2008)
The EuroSIDA study: Regional differences in the HIV-1 epidemic and
treatment response to antiretroviral therapy among HIV-infected patients
across Europe–a review of published results. Cent Eur J Public Health 16: 99–
105.
9. Chiesi A, Mocroft A, Dally LG, Miller V, Katlama C, et al. (1999) Regional
survival differences across Europe in HIV-positive people: the EuroSIDA study.
AIDS 13: 2281–2288.
10. UNAIDS (2009) Argentina County Sitution 2009.
11. Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, et al. (2008) Loss to follow-up
in an international, multicentre observational study. HIV Med 9: 261–269.
12. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, et al. (2003) Decline in
the AIDS and death rates in the EuroSIDA study: an observational study.
Lancet 362: 22–29.
13. Kowalska JD, Friis-Moller N, Kirk O, Bannister W, Mocroft A, et al. (2011) The
Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of
methodology. Epidemiology 22: 516–523.
14. Kowalska JD, Mocroft A, Ledergerber B, Florence E, Ristola M, et al. (2011) A
standardized algorithm for determining the underlying cause of death in HIV
infection as AIDS or non-AIDS related: results from the EuroSIDA study. HIV
Clin Trials 12: 109–117.
15. Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, et al. (1999) Anaemia is
an independent predictive marker for clinical prognosis in HIV-infected patients
from across Europe. EuroSIDA study group. AIDS 13: 943–950.
16. UNAIDS (2010) Global Report:UNAIDS report on the global AIDS epidmic.
17. UNAIDS (2009) Fact sheets. Eastern Europe and Central Asia. Latest
epidemiological trends.
18. van Asten LC, Boufassa F, Schiffer V, Brettle RP, Robertson JR, et al. (2003)
Limited effect of highly active antiretroviral therapy among HIV-positive
injecting drug users on the population level. Eur J Public Health 13: 347–349.
19. Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, et al. (2003)
Adherence and plasma HIV RNA responses to highly active antiretroviral
therapy among HIV-1 infected injection drug users. CMAJ 169: 656–661.
20. Braitstein P, Justice A, Bangsberg DR, Yip B, Alfonso V, et al. (2006) Hepatitis
C coinfection is independently associated with decreased adherence to
AIDS and Non-AIDS Mortality Rates in Europe
PLoS ONE | www.plosone.org 8 July 2012 | Volume 7 | Issue 7 | e41673
antiretroviral therapy in a population-based HIV cohort. AIDS 20: 323–331.
10.1097/01.aids.0000198091.70325.f4 [doi];00002030-200602140-00003 [pii].
21. Murray M, Hogg R, Lima V, May M, Moore D, et al. (2011) The effect of
injecting drug use history on disease progression and death among HIV-positive
individuals initiating combination antiretroviral therapy: collaborative cohort
analysis. HIV Med. 10.1111/j.1468-1293.2011.00940.x [doi].
22. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, et al. (2010) HIV
prevention, treatment, and care services for people who inject drugs: a
systematic review of global, regional, and national coverage. Lancet 375:
1014–1028. S0140-6736(10)60232-2 [pii];10.1016/S0140-6736(10)60232-2
[doi].
23. Sarang A, Rhodes T, Platt L (2008) Access to syringes in three Russian cities:
implications for syringe distribution and coverage. Int J Drug Policy 19 Suppl 1:
S25–S36. S0955-3959(07)00244-7 [pii];10.1016/j.drugpo.2007.11.008 [doi].
24. Hamers FF, Downs AM (2003) HIV in central and eastern Europe. Lancet 361:
1035–1044. S0140-6736(03)12831-0 [pii];10.1016/S0140-6736(03)12831-0
[doi].
25. Friis-Moller N, Sabin CA, Weber R, d’Arminio MA, El-Sadr WM, et al. (2003)
Combination antiretroviral therapy and the risk of myocardial infarction.
N Engl J Med 349: 1993–2003.
26. Lewden C, Salmon D, Morlat P, Bevilacqua S, Jougla E, et al. (2005) Causes of
death among human immunodeficiency virus (HIV)-infected adults in the era of
potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent
role of AIDS. Int J Epidemiol 34: 121–130.
27. Sofi F, Cesari F, Abbate R, Gensini GF, Casini A (2008) Adherence to
Mediterranean diet and health status: meta-analysis. BMJ 337: a1344.
28. Vollset SE (2010) Does the southern European cardiovascular mortality
advantage extend to total mortality? 50-year trends in death risks between 40
and 70 years of age in Western European men and women. Scand J Public
Health 38: 127–134.
29. Deeks SG (2011) HIV infection, inflammation, immunosenescence, and aging.
Annu Rev Med 62: 141–155.
30. UNAIDS (2008) 08 Report on the global AIDS epidemic.
AIDS and Non-AIDS Mortality Rates in Europe
PLoS ONE | www.plosone.org 9 July 2012 | Volume 7 | Issue 7 | e41673
